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Generalized atrichia with papules is a rare disorder
characterized by loss of hair shortly after birth and
development of cutaneous cysts. Mutations in the
hairless gene (HR) cause this phenotype in both
mouse and human. Here we present a case of atri-
chia with papules in a patient with a normal
HAIRLESS gene but with mutations in both alleles of
the VITAMIN D RECEPTOR. The patient exhibited
vitamin D resistant rickets, which was con®rmed by
an absent response of her ®broblasts to 1,25-dihy-
droxyvitamin D3 in vitro. Similar to individuals with
HAIRLESS mutations, her skin showed an absence of
normal hair follicles and the presence of follicular
remnants and cysts. The cyst epithelium contained
keratin-15- and keratin-17-positive cells suggesting
derivation from the hair follicle bulge and the pres-
ence of epithelial stem cells. Although hair loss has
been reported in association with hereditary vitamin
D resistant rickets, we now characterize this alopecia
as clinically and pathologically indistinguishable
from generalized atrichia with papules, which was
previously thought to be caused only by mutations
in HAIRLESS. These ®ndings suggest that VDR and
HR, which are both zinc ®nger proteins, may be in
the same genetic pathway that controls postnatal
cycling of the hair follicle. Key words: alopecia/cysts/
hair follicle/rickets/transcription factors. J Invest Dermatol
117:612±617, 2001
T
he syndrome of atrichia with papular lesions (OMIM
209500), ®rst described in 1954 by Damste and
Prakken, is characterized by permanent hair loss
beginning within the ®rst few months after birth,
and subsequent development of keratin-®lled cysts in
the skin (Damste and Prakken, 1954). Mutations in the HAIRLESS
(HR) gene have been identi®ed as causative in several families with
this condition, which is inherited in an autosomal recessive manner
and does not affect any extracutaneous sites (Ahmad et al, 1998a, b,
1999; Cichon et al, 1998; Zlotogorski et al, 1998; Kruse et al, 1999;
Sprecher et al, 1999b; Aita et al, 2000). The hairless gene encodes a
predicted 127 kD protein that contains a zinc ®nger domain,
suggesting it functions as a transcription factor (Cachon-Gonzalez
et al, 1994; Djabali et al, 2000). Hr null mice develop hair loss and
cysts remarkably similar to patients with atrichia with papules
(Montagna et al, 1952; Mann, 1971; Panteleyev et al, 1999).
Alopecia is a frequent feature of hereditary vitamin D resistant
rickets (HVDRR, OMIM 277440), a rare autosomal recessive
disorder described in multiple kindreds (Beer et al, 1981; Hochberg
et al, 1985; Marx et al, 1986). Similar to families with atrichia with
papules, hair is generally present at birth but then is lost within
12 mo. Hair loss may precede the development of bony rachitic
changes. Remarkably, bony changes often resolve and metabolic
defects can normalize with age, but the alopecia is permanent (Hirst
et al, 1985). Mutations in the VITAMIN D RECEPTOR (VDR),
which functions as a transcription factor, are responsible for
HVDRR associated with atrichia (Rut et al, 1994; Hawa et al,
1996; Whit®eld et al, 1996). Vdr null mice develop metabolic and
bony changes as well as alopecia very similar to humans with the
disorder (Li et al, 1997; Yoshizawa et al, 1997). The alopecia in
HVDRR has not been well characterized, and its similarity to the
alopecia caused by hairless mutations has not been appreciated.
Here, we studied a patient with HVDRR and atrichia who has
distinct mutations in both VDR alleles, with a normal HR gene.
For the ®rst time, we demonstrate that the cutaneous phenotype
associated with HVDRR is remarkably similar to the generalized
atrichia with papules caused by mutations in HR. Similar to patients
with HR mutations, follicular remnants in this patient's skin appear
to possess hair follicle stem cells, some of which generate cutaneous
cysts. Overall, our ®ndings suggest that VDR and HR may be part
of the same molecular pathway necessary for normal hair follicle
cycling.
MATERIALS AND METHODS
Immunohistochemistry Skin was ®xed in formalin and embedded in
paraf®n. Paraf®n sections were immunostained with the mouse
monoclonal antibody DAKO clone C8/144B, which recognizes
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cytokeratin 15 (Lyle et al, 1998), or a rabbit polyclonal antibody raised
against cytokeratin 17 that was kindly provided by Dr. Pierre Coulombe,
Johns Hopkins University School of Medicine, Baltimore, Maryland
(McGowan and Coulombe, 2000). Tissue sections were steamed in
citrate buffer (10 mM sodium citrate, pH 6.77) for 15 min prior to
incubation. After blocking of endogenous peroxidase with hydrogen
peroxidase 6% and washing with blocking agent (1 3 phosphate-
buffered saline, 0.1% Triton X100, 0.1% bovine serum albumin, and 5%
goat serum) for 20 min, the tissue sections were incubated with the C8/
144B antibody, diluted 1:40, or anti-keratin 17 (anti-K17) antibody,
diluted 1:1000, overnight at 4°C. The avidin±biotin complex technique
was used for immunohistochemistry. After washing, the secondary
antibody (biotinylated antimouse or antirabbit IgG), diluted 1:300, was
added and incubated at room temperature. Streptavidin HRP (Gibco
BRL), diluted 1:500, was applied to the slides and incubated for 30 min
at room temperature. After washing, the sections were developed with
diaminobenzidine (Sigma) as the chromogen, and counterstained with
hematoxylin.
Fibroblast proliferation assay Fibroblasts were isolated from a 4 mm
punch biopsy specimen from the patients' scalp, and from normal human
foreskin (control). After trypsinization overnight, ®broblasts were plated
Figure 2. Scalp biopsy from patient with atrichia caused by VDR mutations. Note the absence of normal follicles (A). (B) Higher
magni®cation of solitary follicular remnant boxed in (A). Note bulges of the outer root sheath. (C) Typical cyst in dermis. (D, E) Immunostaining for
K15 (brown/red stain, arrows) con®rms the presence of bulge cells in follicular remnant and cyst basal layers. (F) Immunostaining for K17. Cyst
epithelium is positive. Scale bars: (A) 150 mm; (B, E) 20 mm; (C, D, F) 50 mm.
Figure 1. Appearance of patient with atrichia
caused by VDR mutations. (A) Atrichia of
scalp; (B) sparing of eyelashes (also frequent in
atrichia caused by HR mutations); (C) cysts on
neck skin.
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in a 35 mm dish in Dulbecco's modi®ed Eagle's medium supplemented
with 5% fetal bovine serum. The second passage cultures were fed with
fresh medium and treated with 1,25(OH)2D3 10
±6, 10±8, and 10±10 M on
the ®rst and fourth day of the culture. Proliferation was assessed by
counting cell numbers on the seventh day after dosing. The
antiproliferative activity of 1,25(OH)2D3 was expressed as a percentage
of the control in the absence of 1,25(OH)2D3. Experiments were
performed in triplicate. Error bars in Fig 3 represent standard deviation.
Primer design For ampli®cation of segments of genomic DNA
corresponding to the VDR gene, the primers were designed on the basis
of ¯anking intronic sequences. Each primer pair was optimized using the
program Primer Designer (Educational Software, version 3.0). The
oligomer primers were 20 nucleotides in length, contained no greater
than three identical consecutive bases, minimal secondary structure,
between 45% and 65% G/C content, and were free of the potential for
primer±dimer formation. Amplimers ranged from 196 to 589 bp in size,
and were placed in introns of the VDR gene to span the exons. Primers
were synthesized using an automatic oligonucleotide synthesizer (Applied
Biosystems).
Mutation detection DNA was prepared from peripheral blood
leukocytes according to standard techniques (Sambrook et al, 1989).
Exons and splice junctions were polymerase chain reaction (PCR)
ampli®ed from genomic DNA and sequenced directly in an ABI Prism
310 Automated Sequencer, using an ABI prism dRhodamine Terminator
cycle sequencing Ready Reaction Sequencing Kit (PE Applied
Biosystems), following puri®cation in Centri¯ex Gel Filtration Cartridges
(Edge Biosystems, Gaithersburg, MD). Exon 4 of the VDR gene was
ampli®ed with the following set of primers: 5¢-AGGAGGAAGGTTTC-
CTGGAG-3¢ (sense primer) and 5¢-GGCTCCACTAGTGCTTCTCC-
3¢ (antisense primer). Exon 8 of the VDR gene was ampli®ed with the
following primers: 5¢-CTGGCCATTGCTTCTCACAG-3¢ (sense
primer) and 5¢-TGCTACGTCTCCCTTCAGGT-3¢ (antisense primer).
Identi®cation of the mutation was performed by visual comparison of the
patient's sequence with that of an unrelated, unaffected control
individual.
RESULTS
Clinical description of patient The patient is a 55-y-old
Caucasian woman with a history of vitamin D resistant rickets,
cutaneous cysts, and atrichia. Hair loss ®rst developed within the
®rst 5 wk of life, and by 1 y of age scalp and body hair were nearly
completely absent (Fig 1a). Only eyelashes are present (Fig 1b).
Asymptomatic cutaneous cysts ®rst developed at the age of 5 and
progressively increased in number (Fig 1c). These 0.5±1.0 cm
bluish and ¯esh-colored nodules are concentrated along the jaw
line, neck, chest, and upper arms. She is of short stature (150 cm)
and has bowing of weight-bearing bones. Her teeth and nails are
normal. Her parents are not consanguineous. A brother, her only
sibling, is unaffected.
Calcium, phosphorus, and parathyroid hormone levels were
within normal limits at the time of our examination. As a child,
these levels were markedly abnormal and resistant to treatment with
high doses of vitamin D.
Current management includes incision and cauterization of cysts.
Treatment with topical tretinoin and systemic isotretinoin did not
prevent the development of cysts.
Pathologic examination of skin A scalp biopsy revealed
complete absence of normal hair follicles (Fig 2A), but
occasional small, empty follicular structures were evident in
cross-section in the mid dermis, and these were associated with a
rudimentary sebaceous lobule (Fig 2B) and arrector pili muscle.
Scattered diminutive follicles containing orthokeratin without hair
shafts were present in the super®cial dermis. Some follicles opened
directly to the epidermal surface and contained laminated
orthokeratin. These lesions were reminiscent of ``utricles'' seen in
mice with mutations in hr (Mann, 1971; Panteleyev et al, 1998b). A
biopsy from neck skin revealed multiple mid dermal cysts lined
with an epithelium that resembled outer root sheath (Fig 2C).
Some cysts contained a thin granular layer along the luminal
surface. Granulomatous in¯ammation surrounded portions of a cyst
that contained focal areas of trichilemmal keratinization.
Analysis of hair follicle stem cell reserve Panteleyev et al
(1998b) analyzed the changes in hr/hr mouse skin using markers for
hair follicle epithelium. They determined that the super®cial
cutaneous cysts in the hairless mouse appeared to arise from the hair
follicle bulge, which is thought to possess hair follicle stem cells.
We previously reported that K15 is a marker for the hair follicle
bulge area in human hair follicles (Lyle et al, 1998). In order to
determine whether hair follicle bulge cells are present in the cysts
from this patient with atrichia and rickets, we immunostained the
skin using an antibody that detects K15. K15-positive cells were
present at the bottom of the follicular remnants, which appears to
end at the level of the bulge (Fig 2D). Interestingly, many cysts
possessed K15-positive bulge cells (Fig 2E), suggesting that the
process leading to cyst formation in HVDRR is similar to that
caused by mutations in HR. To further evaluate the upper follicular
origin of these cysts, we also immunostained the scalp tissue with an
antibody that detects K17, which is normally found in the outer
root sheath epithelium, not in the bulb (McGowan and Coulombe,
2000). The scalp cysts also expressed K17 (Fig 2F).
Analysis of sensitivity to vitamin D3 1,25-dihydroxyvitamin
D3, the active form of vitamin D3, decreases cellular proliferation in
a dose-dependent manner in normal cultured human ®broblasts
(MacLaughlin et al, 1985; Smith et al, 1988). Fibroblasts from
patients with HVDRR are resistant to this effect and show no
change in proliferation in response to 1,25-dihydroxyvitamin D3.
In order to evaluate whether ®broblasts from this patient exhibited
resistance to the effects of 1,25-dihydroxyvitamin D3, we treated
®broblasts isolated from the patient's scalp with 1,25-
dihydroxyvitamin D3 in vitro. In contrast to the normal
®broblasts, ®broblasts from this patient showed no response to
the addition of 1,25-dihydroxyvitamin D3 (Fig 3). These ®ndings
of end-organ resistance to 1,25-dihydroxyvitamin D3 are most
consistent with mutations in the VDR gene.
Analysis of HR and VDR genes Because the atrichia with
papular phenotype of this patient was identical to that of patients
carrying mutations in the HR gene, we screened for mutations in
this gene in this patient with HVDRR with atrichia. By direct
DNA sequencing of this patient's HR gene, we found no
mutations. Knowing that HVDRR has been associated with
mutations in the VDR gene, we screened for a mutation in the
human VDR gene. Exons and splice junctions were PCR ampli®ed
from genomic DNA and sequenced directly. Sequence analysis of
exon 4 of the VDR gene from the affected individual revealed a
Figure 3. Fibroblasts from the patient with HVDRR and atrichia
are resistant to the effects of 1,25(OH)2vitaminD3. Increasing
concentrations of 1,25(OH)2vitaminD3 suppress growth of normal
®broblasts but not growth of the patient's ®broblasts in vitro.
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heterozygous single base pair deletion at nucleotide position 366,
designated 366delC. This deletion led to a frameshift and
downstream premature termination codon at nucleotide position
420 within exon 4 (Fig 4).
The second mutation was identi®ed in exon 8 of the VDR gene.
Direct sequence analysis of exon 8 revealed a heterozygous G-to-A
transition in the proband. The G-to-A transition occurred at the
®rst base of the glutamic acid (E) residue at position 985 (GAG),
leading to a missense mutation converting the glutamic acid residue
to a lysine (K) residue (AAG), and was designated E329K. The
mutation destroyed the cleavage site for the restriction endonu-
clease Mnl1 (GGAG), which was used to con®rm the presence of
the mutation in genomic DNA, in addition to direct sequencing.
To verify that the missense mutation was not a normal polymorphic
variant within the VDR gene, we screened for the mutation by a
combination of direct sequencing and restriction digestion in a
control population consisting of 50 unrelated, unaffected individ-
uals. No evidence for the mutant allele was found in these
individuals, suggesting that E329K is a pathogenetic mutation. The
proband therefore is a compound heterozygote for two different
VDR mutations (366delC/E329K). Screening of DNA from her
unaffected brother revealed that he does not carry mutations in
either of the VDR genes. The pedigree is consistent with autosomal
recessive inheritance. No other family members are available for
screening. Given that we were limited to analyzing DNA from the
proband and her brother, it is possible that one of the mutations
arose de novo.
DISCUSSION
The presence of hair at birth in both HVDRR and atrichia with
papules suggests that hair follicle development is normal in these
Figure 4. Genetic analysis of the patient. (A)
The pedigree is suggestive of autosomal recessive
inheritance. (B) Comparison of mutant and wild-
type DNA sequence of exon 4 from VDR. Arrow
points to the deletion of a single nucleotide at
position 366 (366delC), which results in a frame
shift and downstream premature termination
codon at nucleotide 420. (C) Comparison of
mutant and wild-type DNA sequence of exon 8
of VDR. Arrow points to a missense mutation at
nucleotide 985 leading to conversion of glutamic
acid to lysine (E329K).
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conditions. Indeed, both vdr and hr mutant mice develop normal
hair follicles and hair. Subsequent hair loss, beginning 3±4 wk after
birth, suggests a defect in hair follicle cyclingÐeither in catagen,
telogen, and/or anagen onset. In hairless mice, Panteleyev et al
(1999) con®rmed that a defect in catagen was responsible for the
phenotype. Normally during catagen, the epithelial cells in the
lower portion of the hair follicle undergo apoptosis, and this results
in cessation of hair growth and a precisely orchestrated involution
of the lower follicle leading to telogen (Cotsarelis, 1997; Paus and
Cotsarelis, 1999). After telogen, the follicle reenters anagen and the
hair reforms. In the hairless phenotype, hair regrowth is disrupted
because the lower follicle disintegrates during catagen (Panteleyev
et al, 1998b, 1999), and the normal juxtaposition of epithelial stem
cells in the bulge and mesenchymal cells in the hair follicle dermal
papilla is not reestablished during telogen. This prevents mesench-
ymal±epithelial interactions thought to be necessary for reentry into
anagen (Cotsarelis et al, 1990). The preservation of this patient's
eyelashes may re¯ect the eyelashes' normal brief catagen stage in
which the follicle only shortens slightly. In this type of follicle,
VDR and HR defects may not suf®ciently disrupt hair follicle
architecture during catagen to result in aberrant hair follicle cycling.
Vibrissae follicles also have short catagen stages (Oshima et al,
2001), and these follicles are also often preserved in hr mutant mice
(Mann and Straille, 1961).
In vdr mutant mice also, hair loss begins around 3±4 wk of age
(Li et al, 1997; Yoshizawa et al, 1997). Interestingly, the develop-
ment of many of the metabolic abnormalities in vdr ±/± mice can
be prevented on a diet that normalizes mineral ion homeostasis;
however, the alopecia still develops (Li et al, 1998). This ®nding
supports the concept that the hair defect is a direct result of the vdr
mutation rather than a secondary effect. Further evidence that vdr
mutations cause aberrant hair follicle cycling was recently reported
by Sakai and Demay (2000) who demonstrated that depilation of
18-d-old vdr ±/± mice resulted in profoundly impaired hair
regrowth. Thus, both humans and mice with mutations in either
the hairless or the vitamin D receptor genes appear to have similar
phenotypes of normal hair follicle development with aberrant hair
follicle cycling.
Another similarity between hr and vdr mutant phenotypes is the
development of cutaneous cysts. Both hr and vdr mutant mice
develop cutaneous cysts, and humans with HR mutations also
develop cysts that account for the papules that are part of the
syndrome of atrichia with papules (Ahmad et al, 1998a; Sprecher
et al, 1999a). Cysts are rarely mentioned in clinical descriptions of
patients with HVDRR (Beer et al, 1981; Hochberg et al, 1985;
Marx et al, 1986), although pathologic descriptions of skin from
HVDRR patients are rare and include a report of ``normal follicles
without hair shafts'' (Hochberg et al, 1985). Our patient clearly
developed numerous cutaneous cysts as well as atrichia in a manner
that closely mimics the phenotype of patients and mice carrying
mutations in hr.
Cutaneous cysts in hr mutant mice are thought to arise from
follicular remnants that survive after the follicle breaks apart during
catagen (Panteleyev et al, 1998a, 1999). Based on keratin expression
and morphologic evidence, many of these cysts appear to arise from
the hair follicle bulge (Panteleyev et al, 1998b). The cyst epithelium
expresses K17, which is normally found in the hair follicle outer
root sheath (Panteleyev et al, 1998b; McGowan and Coulombe,
2000). We previously showed that K15 is a marker for bulge cells
(Lyle et al, 1998) and that it is expressed by many tumors that are
thought to originate from the bulge (Jih et al, 1999). The K15 and
K17 positivity of the cystic epithelium and follicular remnants in
this patient with a VDR mutation further supports the concept that
HR and VDR mutations lead to indistinguishable cutaneous
phenotypes. Furthermore, our ®ndings suggest that epithelial
stem cells, which may replenish the epidermis with keratinocytes,
are present in HVDRR.
The realization that mutations in the HR and VDR genes cause
indistinguishable cutaneous phenotypes of generalized atrichia
suggests that these two proteins are components of the same
molecular pathway that is necessary for normal involution of the
follicle during catagen. VDR is a member of the steroid binding
receptor family and acts as a transcription factor. VDR possesses
two zinc ®nger domains in the amino terminus and a ligand (1,25-
dihydroxyvitamin D3) binding domain at the carboxy-terminus.
The upstream zinc ®nger domain binds to DNA whereas the
downstream domain is important for partnering with other
proteins, including RXR. To date, at least eight missense mutations
in the zinc ®nger domains have been described, and all of these
patients exhibit HVDRR and atrichia (for review see Malloy et al,
1999). Similarly, premature termination mutations affecting these
sites also cause HVDRR and atrichia. Interestingly, although most
mutations in the ligand binding domain cause HVDRR and
alopecia, three mutations have been described that resulted in
HVDRR without alopecia. This suggests that the binding of 1,25-
dihydroxyvitamin D3 to VDR may not be necessary for normal
catagen, but that the functions of the zinc ®nger domains, namely
DNA binding and heterodimerization with other proteins, are
necessary for regulation of the hair cycle. This is further supported
by the fact that other types of vitamin D de®ciency (caused by 1-a-
hydroxylase for example), in which the VDR is normal but ligand
binding is absent, do not cause alopecia.
Our patient's upstream mutation is located in the ``hinge region''
of the gene, which lies between the DNA binding domain and the
ligand binding domain. The function of the hinge region is not
known, but it may play a role in the binding of VDR to other
steroid receptors. VDR, like other members of the steroid binding
receptor family (e.g. estrogen receptor, thyroid hormone receptor),
is known to partner with RXR. RXR-alpha ablation in mouse
epidermis and hair follicle outer root sheath has recently been
shown to cause a very similar phenotype to the hr and vdr mutant
mice (Li et al, 2001). These mice also develop alopecia and
cutaneous cysts, and have poor hair regrowth after depilation. In
addition, hr, vdr, and RXR-alpha are all expressed in hair follicle
keratinocytes (Reichrath et al, 1994; Panteleyev et al, 2000; Li et al,
2001). Thus, we propose that VDR, HR, and RXR-alpha are all
in the same or convergent genetic pathways necessary for activation
of genes controlling catagen. One possibility is that these proteins
form a complex that binds to transcriptional elements involved in
the control of catagen. This concept is supported by the fact that
HR also has a zinc ®nger domain and is known to bind to thyroid
receptor and modulate transcription of genes containing thyroid-
responsive elements (Thompson and Bottcher, 1997). HR does not
bind RXR or other steroid receptors, however, including the
corticosteroid and mineralocorticoid receptors. Therefore, another
possibility is that these proteins independently bind to separate sites
on the same promoter that controls transcription of genes
controlling catagen. Clearly, future studies are required to deter-
mine the exact relationship between HR and VDR, as well as the
components of these genes that control hair follicle cycling.
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